Overview

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

Status:
Completed

Trial end date:
2019-09-01

Target enrollment:

Participant gender:

Summary

To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo on basal cardiorenal and humoral function and on the integrated cardiorenal and humoral response to acute sodium loading in subjects with preclinical systolic dysfunction (PSD) and renal (kidney) dysfunction.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Mayo Clinic

Treatments:

Tadalafil